tradingkey.logo

Indian drugmaker Dr Reddy's up on partnership to develop cancer immunotherapy

ReutersJun 5, 2025 4:24 AM

India's Dr Reddy's Laboratories REDY.NS climbs 2.2% to 1,278.80 rupees

Stock top gainer on pharma index .NIPHARM, which is trading 0.9% higher

Drugmaker partners with U.S.-listed biosimilars maker Alvotech ALVO.O to develop a biosimilar for Merck's MRK.N cancer immunotherapy Keytruda

Keytruda, which belongs to a class of immunotherapy called PD-L1 inhibitor, had global sales of $29.5 bln in 2024 - REDY

REDY and ALVO will jointly develop the therapy and will have rights to commercialize the product globally - companies

REDY third-cheapest stock with fwd 12-mth PE ratio of 18.8 on pharma index

YTD, REDY down 7.5% vs pharma index's 8% decline

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI